Infantile spasms: Etiology, lead time and treatment response in a resource limited setting

Priyanka Surana1,2, Joseph D Symonds2,3, Prabhar Srivastava1

  • 1Departments' of Pediatrics, Pediatric Neurology & Radio Diagnosis, Santokba Durlabhji Memorial Hospital, Jaipur, India.

Epilepsy & Behavior Reports
|November 16, 2020
PubMed

Insights

Timely treatment is crucial for infantile spasms (IS). Delays in initiating appropriate care, particularly in resource-limited settings, significantly worsen treatment outcomes and increase spasm resistance.

Area of Science:

  • Neurology
  • Pediatrics
  • Genetics

Background:

  • Infantile spasms (IS) are a severe epilepsy syndrome in infants.
  • Etiology and treatment lead time significantly impact IS outcomes.
  • Limited resource settings present unique challenges in managing IS.

Purpose of the Study:

  • To explore the causes (etiology) of infantile spasms.
  • To determine the time from IS onset to treatment initiation (lead time).
  • To evaluate the impact of etiology and lead time on treatment responsiveness in a resource-limited setting.

Main Methods:

  • Retrospective study of 113 IS patients with onset age ≤12 months.
  • Patients categorized into Structural, Genetic, and Unknown etiological groups.
  • Analysis of clinical data, neuroimaging, genetic results, and treatment response.

Main Results:

  • Etiology was identified in 83.1% of patients; neonatal hypoglycemic brain injury (NHBI) was most common (36%).
  • Structural etiology was associated with lower treatment resistance (p=0.013).
  • A longer treatment lead time (median 60 days) significantly correlated with resistant spasms (p=0.0015).

Conclusions:

  • NHBI is a primary cause of IS in this population.
  • Significant delays in treatment initiation negatively affect spasm resolution.
  • Optimizing early diagnosis and treatment is critical for improving outcomes in infantile spasms.

Related Concept Videos

Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein01:20

Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein

Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
644
Epilepsy and Seizures: Overview01:24

Epilepsy and Seizures: Overview

Epilepsy is a chronic neurological disease marked by recurrent, unpredictable seizures. These seizures are caused by abnormal electrical discharges in the brain, leading to behavior, sensation, or consciousness alterations. They can also cause transient impairment of awareness, interfering with daily activities.
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
928
Seizures: Classification01:13

Seizures: Classification

Epilepsy is primarily characterized by unpredictable seizures, either provoked by an identifiable factor, such as injury or illness, or unprovoked, occurring spontaneously without apparent cause.
Seizures are typically classified into two main categories: focal and generalized seizures.
Focal Seizures
Focal seizures originate from specific regions of the brain. These seizures are further sub-classified into two types:
1.1K
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
120